Akero Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Akero Therapeutics

28/02/2025 13:11

Akero Therapeutics Inc AKRO.OQ reported a quarterly adjusted loss of 99 cents​​ per share for the quarter ended December 31, identical to the same quarter last year.  The mean expectation of nine analysts for the quarter was for a loss of $1.15 per share. Wall Street expected results to range from $-1.39 to $-1.07 per share.

Reported revenue was zero​; analysts expected zero.

Akero Therapeutics Inc's reported EPS for the quarter was a loss of 99 cents​.

The company reported a quarterly loss of $70.03 million.

Akero Therapeutics Inc shares had risen by 71.6% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 1% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Akero Therapeutics Inc is $77.50

This summary was machine generated from LSEG data February 28 at 01:11 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-1.15
-0.99
Beat
Sep. 30 2024
-0.90
-1.05
Missed
Jun. 30 2024
-0.90
-0.81
Beat
Mar. 31 2024
-0.95
-0.90
Beat